Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded from surgery and / or radiotherapy

Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign peripheral nervous system tumors and various benign or locally malignant tumors of the central nervous system. Many complications occur in children more often than in adults and significantly shorten the survival period of affected children.

Stabilization or (desirable) regression of the primary tumor

Stabilization or (desirable) regression of the patient's primary tumor and other tumors for at least 6 months after the end of treatment

No related papers found yet.

Poland